盐酸多柔比星联合环磷酰胺治疗乳腺癌患者的临床疗效  

Clinical efficacy of doxorubicin hydrochloride combined with cyclophosphamide in the treatment of breast cancer patients

作　　者：任征 REN Zheng(Shenyang Fourth People's Hospital,Shenyang 110000,China)

机构地区：[1]沈阳市第四人民医院,110000

出　　处：《中国实用医药》2021年第5期34-36,共3页China Practical Medicine

摘　　要：目的针对乳腺癌患者采用盐酸多柔比星联合环磷酰胺治疗的疗效进行分析。方法 90例乳腺癌患者,根据化疗方式不同分为对比组和观察组,每组45例。对比组患者采取常规化疗方式(多西他赛、吡柔比星联合顺铂化疗法)进行治疗,观察组患者采取新辅助化疗方式(多西他赛、盐酸多柔比星联合环磷酰胺化疗法)进行治疗。对比两组患者近期疗效、远期疗效、化疗前后血管新生指标[血管内皮生长因子A(VEGFA)、血管内皮生长因子B(VEGFB)]、化疗后不良反应发生情况。结果观察组患者近期化疗有效率为82.22%(37/45),明显高于对比组的62.22%(28/45),差异具有统计学意义(P<0.05)。观察组患者远期化疗有效率为71.11%(32/45),明显高于对比组的48.89%(22/45),差异具有统计学意义(P<0.05)。化疗后,观察组患者VEGFA为(82.63±10.63)ng/ml,低于对比组的(138.63±18.46)ng/ml,差异具有统计学意义(P<0.05)。化疗后,观察组患者VEGFB为(77.52±7.95)ng/ml,低于对比组的(126.95±5.69)ng/ml,差异具有统计学意义(P<0.05)。观察组患者不良反应发生率24.44%(11/45)低于对比组的44.44%(20/45),差异具有统计学意义(P<0.05)。结论乳腺癌患者采用盐酸多柔比星联合环磷酰胺治疗,能够有效提高患者化疗效率,改善患者临床症状,使患者血管新生指标得到改善,降低患者化疗期间的不良反应发生率,具有良好治疗价值。Objective To analyze the efficacy of doxorubicin hydrochloride combined with cyclophosphamide in the treatment of breast cancer patients.Methods A total of 90 breast cancer patients were divided into control group and observation group according to different chemotherapy methods,with 45 cases in each group.The control group received conventional chemotherapy(docetaxel,pirarubicin combined with cisplatin),and the observation group was treated with neoadjuvant chemotherapy(docetaxel,doxorubicin hydrochloride combined with cyclophosphamide).The short-term efficacy,long-term efficacy,angiogenesis indicators[vascular endothelial growth factor A(VEGFA),vascular endothelial growth factor B(VEGFB)]before and after chemotherapy,occurrence of adverse reactions after chemotherapy were compared between the two groups.Results The effective rate of short-term chemotherapy of the observation group was 82.22%(37/45),which was obviously higher than 62.22%(28/45)of the control group,and the difference was statistically significant(P<0.05).The effective rate of long-term chemotherapy of the observation group was 71.11%(32/45),which was obviously higher than 48.89%(22/45)of the control group,and the difference was statistically significant(P<0.05).After chemotherapy,the VEGFA of the observation group was(82.63±10.63)ng/ml,which was lower than(138.63±18.46)ng/ml of the control group,and the difference was statistically significant(P<0.05).After chemotherapy,the VEGFB of the observation group was(77.52±7.95)ng/ml,which was lower than(126.95±5.69)ng/ml of the control group,and the difference was statistically significant(P<0.05).The incidence of adverse reactions of the observation group was 24.44%(11/45),which was lower than 44.44%(20/45)of the control group,and the difference was statistically significant(P<0.05).Conclusion Doxorubicin hydrochloride combined with cyclophosphamide shows good therapeutic value for patients with breast cancer,which can effectively improve the efficiency of chemotherapy,improve the clinical symptoms

关 键 词：盐酸多柔比星 环磷酰胺 乳腺癌 联合治疗 临床效果 化疗 

分 类 号：R737.9[医药卫生—肿瘤]